Sponsor-Investigators

Brian Rini

HCRN-GU15-223

Randomized Phase II trial comparing sequential first-line sunitinib and second-line avelumab versus first-line avelumab and second-line sunitinib for metastatic renal cell carcinoma: SUAVE trial: HCRN GU15-223

Status

Closed

Cancer Types

Kidney

Locations